Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glutamate receptor, ionotropic, N-methyl D-aspartate 1 | References | |
Homo sapiens | glutamate receptor, ionotropic, AMPA 2 | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | glutamate receptor, ionotropic, AMPA 2 | 883 aa | 810 aa | 34.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | glutamate receptor subunit protein glur | 0.0071 | 0.0664 | 0.124 |
Echinococcus granulosus | glutamate receptor subunit protein glur | 0.0071 | 0.0664 | 0.124 |
Brugia malayi | Glutamate receptor 2 precursor | 0.0106 | 0.4271 | 0.5 |
Echinococcus granulosus | glutamate receptor NMDA | 0.0095 | 0.3188 | 0.5951 |
Brugia malayi | Glutamate receptor 1 precursor | 0.0106 | 0.4271 | 0.5 |
Echinococcus multilocularis | glutamate receptor, ionotrophic, AMPA 3 | 0.0116 | 0.5357 | 1 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0095 | 0.3188 | 0.5951 |
Echinococcus granulosus | glutamate receptor 2 | 0.0116 | 0.5357 | 1 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0106 | 0.4274 | 0.7979 |
Loa Loa (eye worm) | glutamate receptor 1 | 0.0106 | 0.4271 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0115 | 0.5307 | 0.9906 |
Echinococcus granulosus | glutamate receptor ionotrophic AMPA 3 | 0.0116 | 0.5357 | 1 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0116 | 0.5357 | 1 |
Echinococcus granulosus | glutamate receptor 2 | 0.0096 | 0.3238 | 0.6045 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0106 | 0.4271 | 0.7972 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0115 | 0.5307 | 0.9906 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0106 | 0.4274 | 0.7979 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0096 | 0.3238 | 0.6045 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 0.12 uM | Positive allosteric modulation of GluN1/GluN2A receptor (unknown origin) expressed in CHO cells assessed as increase in glutamate-induced calcium flux measured at time interval of 5 mins in presence of saturating glycine by calcium dye-based fluorescence assay | LITERATURE. | 28105280 |
EC50 (ADMET) | = 16 uM | Positive allosteric modulation of human GluA2 receptor flop isoform assessed as increase in glutamate-induced calcium flux measured at time interval of 5 mins in presence of saturating glycine by calcium dye-based fluorescence assay | LITERATURE. | 28105280 |
EC50 (ADMET) | = 27 uM | Positive allosteric modulation of human GluA2 receptor flip isoform assessed as increase in glutamate-induced calcium flux measured at time interval of 5 mins in presence of saturating glycine by calcium dye-based fluorescence assay | LITERATURE. | 28105280 |
Emax (ADMET) | = 27 % | Positive allosteric modulation of human GluA2 receptor flip isoform assessed as increase in glutamate-induced calcium flux at 125 uM measured at time interval of 5 mins in presence of saturating glycine by calcium dye-based fluorescence assay relative to glutamate | LITERATURE. | 28105280 |
Emax (ADMET) | = 77 % | Positive allosteric modulation of human GluA2 receptor flop isoform assessed as increase in glutamate-induced calcium flux at 125 uM measured at time interval of 5 mins in presence of saturating glycine by calcium dye-based fluorescence assay relative to glutamate | LITERATURE. | 28105280 |
Emax (binding) | = 142 % | Positive allosteric modulation of GluN1/GluN2A receptor (unknown origin) expressed in CHO cells assessed as increase in glutamate-induced calcium flux at 125 uM measured at time interval of 5 mins in presence of saturating glycine by calcium dye-based fluorescence assay relative to glutamate | LITERATURE. | 28105280 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.